“…Based on analysis of various modern spectroscopic data, such as high-resolution mass spectrometry, 1D and 2D nuclear magnetic resonance (NMR), spectroscopy as well as comparison with corresponding results in the literature, the chemical structures of the isolated compounds were identified as 2,4,6-trihydroxy-acetophenone ( 1 ), 1-(2,4,6-trihydroxy-phenyl)-propan-1-one ( 2 ), phlorobutyrophenone ( 3 ), 5-acetyl-2,4,6-trihydroxyacetophenone ( 4 ), 1,3-(2,4,6-trihydroxyphenyl)dipropanone ( 5 ), 1,3-(2,4,6-trihydroxyphenyl)dibutanone ( 6 ), 1-(2,4,6-trihydroxy-3-methylphenyl)propanone ( 7 ), 1-(2, 4, 6-trihydroxy-3-methylphenyl) butanone ( 8 ), 1-(2, 4, 6-trihydroxy-3-methylphenyl) pentanone ( 9 ), tripropionylphloroglucinol ( 10 ), tributyrylphloroglucinol ( 11 ), bis-phlorobutyrophenone ( 12 ), dryopidin PB ( 13 ), methylene-bis-phlorobutyrophenone ( 14 ), araspidin BB ( 15 ), norflavaspidic acid AP ( 16 ), norflavaspidic acid AB ( 17 ), norflavaspidic acid PB ( 18 ), norflavaspidic acid BB ( 19 ), flavaspidic acid AA ( 20 ), flavaspidic acid AP ( 21 ), flavaspidic acid AB ( 22 ), flavaspidic acid PB ( 23 ), albaspidin AA ( 24 ), dryopcrassirine AB ( 25 ), nortrisflavaspidic acid ABB ( 26 ), trisflavaspidic acid ABB ( 27 ), trisflavaspidic acid BBB ( 28 ), filixic acid ABA ( 29 ), and dryocrassin ABBA ( 30 ) ( Figure 1 ). All isolated compounds were evaluated for their PTP1B inhibitory activities through in vitro assays, and some exhibited significant inhibitory effects [ 23 ].…”